About: Description of a new biosafe procedure for cytological specimens from patients with COVID‐19 processed by liquid‐based preparations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Description of a new biosafe procedure for cytological specimens from patients with COVID‐19 processed by liquid‐based preparations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Description of a new biosafe procedure for cytological specimens from patients with COVID‐19 processed by liquid‐based preparations
Creator	Gian, ; Cancellieri, Alessandra Cianfrini, Federica Curatolo, Mariangela Fadda, Guido Martini, Maurizio Mulè, Antonino Straccia, Patrizia Chiara Brunelli, ; Esther, ; Rossi, Diana Zannoni, Franco
Source	Medline; PMC
abstract	BACKGROUND: Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and represents the causative agent of a potentially fatal disease. The spread of the infection and the severe clinical disease have led to the widespread adoption of social distancing measures. Special attention and efforts to protect or reduce transmission have been applied at all social levels, including health care operators. Hence, this reports focuses on the description of a new protocol for the safe management of cytological samples processed by liquid‐based cytology (LBC) with an evaluation of the changes in terms of morphology and immunoreactivity. METHODS: From March 11 to April 25, 2020, 414 cytological cases suspicious for SARS‐CoV‐2 were processed with a new virus‐inactivating method suggested by Hologic, Inc, for all LBC specimens. RESULTS: The samples showed an increased amount of fibrin in the background. A slight decrease in cellular size was also observed in comparison with the standard method of preparation. Nonetheless, the nuclear details of the neoplastic cells were well identified, and the immunoreactivity of the majority of those cells was maintained. The cell blocks did not show significant differences in morphology, immunoreactivity, or nucleic acid stability. CONCLUSIONS: Despite some minor changes in the morphology of the cells, the results of this study highlight that the adoption of the new protocol for the biosafety of LBC‐processed samples in pathology laboratories is important for minimizing the risk for personnel, trainees, and cytopathologists without impairing the diagnostic efficacy of the technique.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1002/cncy.22341
bibo:pmid	32767745
has license	no-cc
sha1sum (hex)	39879c6e59345bc988186242d90efda1137e74b7
schema:url	https://doi.org/10.1002/cncy.22341
resource representing a document's title	Description of a new biosafe procedure for cytological specimens from patients with COVID‐19 processed by liquid‐based preparations
has PubMed Central identifier	PMC7436212
has PubMed identifier	32767745
schema:publication	Cancer Cytopathol
resource representing a document's body	covid:39879c6e59345bc988186242d90efda1137e74b7#body_text
is schema:about of	named entity 'fatal' named entity 'focuses' named entity 'Despite' named entity 'infection' named entity 'MARCH' named entity 'MEASURES' named entity 'TRANSMISSION' named entity 'MAINTAINED' named entity 'CYTOLOGICAL' named entity 'LABORATORIES' named entity 'IMPORTANT' named entity 'CAUSED BY' named entity 'VIRUS' named entity 'TECHNIQUE' named entity 'MINOR' named entity 'ATTENTION' named entity 'STUDY' named entity 'INCREASED AMOUNT' named entity 'SPECIMENS' named entity 'LBC' named entity 'Inc' named entity 'study' named entity 'cases' named entity 'protocol' named entity 'liquid-based cytology' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'morphology' named entity 'Cytological' named entity 'COVID-19' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'lower respiratory tract infections' named entity 'malignancy' named entity 'World Health Organization' named entity 'Qiagen' named entity 'morphology' named entity 'hyperchromasia' named entity '2019-nCoV' named entity 'biosafety' named entity 'LBC' named entity 'SARS-CoV-2' named entity 'cytological' named entity 'nucleic acid' named entity 'laboratory investigations' named entity 'coronavirus' named entity 'epidermal growth factor receptor' named entity 'morphological' named entity 'SARS-CoV-2' named entity 'immunoreactivity' named entity 'pneumonia' named entity 'nuclear atypia' named entity 'cytological' named entity 'pathology' named entity 'severe acute respiratory syndrome' named entity 'fine-needle aspiration' named entity 'exons' named entity 'coronavirus' named entity 'needle biopsies' named entity 'SARS-CoV-2' named entity 'cellular material' named entity 'LBC' named entity 'COVID-19 pandemic' named entity 'Gemelli University Hospital' named entity 'Hologic' named entity 'Catholic University of the Sacred Heart' named entity 'International Committee on Taxonomy of Viruses' named entity 'lung' named entity 'genome' named entity 'oropharyngeal' named entity 'thyroid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software